The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Abiomed Inc

Nasdaq: ABMD
Last

(U.S.) $118.08

Today's change+1.43 +1.23%
Updated December 8 4:00 PM EST. Delayed by at least 15 minutes.
 

Abiomed Inc

Nasdaq: ABMD
Last

(U.S.) $118.08

Today's change+1.43 +1.23%
Updated December 8 4:00 PM EST. Delayed by at least 15 minutes.

Abiomed Inc Hits New 20-day High

Abiomed Inc closed up Thursday by (U.S.)$1.43 or 1.23% to (U.S.)$118.08 and setting a new 20-day high. Over the last five days, shares have gained 9.95% and 30.79% year to date. Shares have outperformed the S&P 500 by 27.82% during the last year.

Key company metrics

  • Open(U.S.) $116.82
  • Previous close(U.S.) $116.65
  • High(U.S.) $118.79
  • Low(U.S.) $115.25
  • Bid / Ask(U.S.) $99.00 / (U.S.) $119.78
  • YTD % change+30.79%
  • Volume446,347
  • Average volume (10-day)456,507
  • Average volume (1-month)789,958
  • Average volume (3-month)497,074
  • 52-week range(U.S.) $67.81 to (U.S.) $132.95
  • Beta0.51
  • Trailing P/E122.60×
  • P/E 1 year forward104.31×
  • Forward PEG3.79×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.96
Updated December 8 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.24%

Based on its net profit margin of 11.24%, Abiomed Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.38%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue1031039486
Total other revenue--------
Total revenue1031039486
Gross profit86887973
Total cost of revenue17151513
Total operating expense88827468
Selling / general / administrative53514542
Research & development18161414
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income15212017
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax15212017
Income after tax9131111
Income tax, total6997
Net income9131111
Total adjustments to net income--------
Net income before extra. items9131111
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9131111
Inc. avail. to common incl. extra. items9131111
Diluted net income9131111
Dilution adjustment--0----
Diluted weighted average shares45454545
Diluted EPS excluding extraordinary itemsvalue per share0.200.290.240.23
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.200.290.240.23